X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Aurobindo Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs AUROBINDO PHARMA - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA AUROBINDO PHARMA CIPLA/
AUROBINDO PHARMA
 
P/E (TTM) x 43.7 17.7 246.0% View Chart
P/BV x 3.6 5.8 62.4% View Chart
Dividend Yield % 0.4 0.4 99.2%  

Financials

 CIPLA   AUROBINDO PHARMA
EQUITY SHARE DATA
    CIPLA
Mar-17
AUROBINDO PHARMA
Mar-16
CIPLA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs6221,541 40.4%   
Low Rs458582 78.7%   
Sales per share (Unadj.) Rs181.9237.5 76.6%  
Earnings per share (Unadj.) Rs12.933.9 38.0%  
Cash flow per share (Unadj.) Rs29.340.6 72.2%  
Dividends per share (Unadj.) Rs2.002.50 80.0%  
Dividend yield (eoy) %0.40.2 157.2%  
Book value per share (Unadj.) Rs155.7120.6 129.1%  
Shares outstanding (eoy) m804.51585.17 137.5%   
Bonus/Rights/Conversions ESOPPREF-  
Price / Sales ratio x3.04.5 66.5%   
Avg P/E ratio x42.031.3 133.9%  
P/CF ratio (eoy) x18.426.2 70.4%  
Price / Book Value ratio x3.58.8 39.4%  
Dividend payout %15.57.4 210.5%   
Avg Mkt Cap Rs m434,516621,041 70.0%   
No. of employees `00023.013.3 173.4%   
Total wages/salary Rs m26,33815,508 169.8%   
Avg. sales/employee Rs Th6,349.110,457.6 60.7%   
Avg. wages/employee Rs Th1,143.01,167.1 97.9%   
Avg. net profit/employee Rs Th449.31,491.6 30.1%   
INCOME DATA
Net Sales Rs m146,302138,961 105.3%  
Other income Rs m2,2871,663 137.5%   
Total revenues Rs m148,589140,624 105.7%   
Gross profit Rs m24,75832,056 77.2%  
Depreciation Rs m13,2293,926 337.0%   
Interest Rs m1,5942,568 62.1%   
Profit before tax Rs m12,22227,225 44.9%   
Minority Interest Rs m039 0.0%   
Prior Period Items Rs m-700-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,7987,444 24.1%   
Profit after tax Rs m10,35419,820 52.2%  
Gross profit margin %16.923.1 73.4%  
Effective tax rate %14.727.3 53.8%   
Net profit margin %7.114.3 49.6%  
BALANCE SHEET DATA
Current assets Rs m87,370100,015 87.4%   
Current liabilities Rs m33,08174,759 44.2%   
Net working cap to sales %37.118.2 204.2%  
Current ratio x2.61.3 197.4%  
Inventory Days Days87107 81.0%  
Debtors Days Days62110 56.9%  
Net fixed assets Rs m111,56752,350 213.1%   
Share capital Rs m1,609585 274.9%   
"Free" reserves Rs m123,64567,707 182.6%   
Net worth Rs m125,25470,567 177.5%   
Long term debt Rs m36,4548,472 430.3%   
Total assets Rs m209,532156,994 133.5%  
Interest coverage x8.711.6 74.7%   
Debt to equity ratio x0.30.1 242.4%  
Sales to assets ratio x0.70.9 78.9%   
Return on assets %5.714.3 40.0%  
Return on equity %8.328.1 29.4%  
Return on capital %8.537.7 22.5%  
Exports to sales %34.251.0 67.0%   
Imports to sales %8.318.8 44.2%   
Exports (fob) Rs m50,05070,927 70.6%   
Imports (cif) Rs m12,20326,193 46.6%   
Fx inflow Rs m51,06671,015 71.9%   
Fx outflow Rs m17,67828,799 61.4%   
Net fx Rs m33,38842,216 79.1%   
CASH FLOW
From Operations Rs m23,82417,596 135.4%  
From Investments Rs m-13,127-13,801 95.1%  
From Financial Activity Rs m-13,239-198 6,676.0%  
Net Cashflow Rs m-2,4783,597 -68.9%  

Share Holding

Indian Promoters % 16.0 54.1 29.6%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 8.0 153.5%  
FIIs % 23.7 27.7 85.6%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 10.2 256.9%  
Shareholders   161,166 69,601 231.6%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   PANACEA BIOTECH  DISHMAN PHARMA  J.B.CHEMICALS  NATCO PHARMA  DIVIS LABORATORIES  

Compare CIPLA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Post Noon Sell-Off; Infosys Falls 5.4%(Closing)

Share markets in India witnessed a sharp fall in the final minutes of trade. At the closing bell, the BSE Sensex closed lower by 266 points. While, the NSE Nifty finished lower by 83 points.

Related Views on News

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Aug 21, 2017 (Close)

TRACK CIPLA

CIPLA - FULFORD INDIA COMPARISON

COMPARE CIPLA WITH

MARKET STATS